Leber Congenital Amaurosis Market Research: Growth Projections and Trends 2030

Uncover key drivers, emerging technologies, and competitive movements shaping the leber congenital amaurosis market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Leber Congenital Amaurosis Market be in 2030 compared with 2026?

The leber congenital amaurosis market size has experienced robust expansion in recent years. This market is projected to expand from $1.06 billion in 2025 to reach $1.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. Historically, this upward trend was driven by factors such as limited therapeutic alternatives for inherited retinal disorders, a rise in awareness concerning rare genetic eye conditions, progress in retinal imaging techniques, an increase in pediatric ophthalmology services, and initial investigations into gene replacement therapy.

The market size for leber congenital amaurosis is anticipated to experience robust expansion over the coming years. It is projected to achieve a value of $1.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. This growth during the forecast period can be attributed to several factors, including increasing investment in ophthalmic gene therapy research, the expansion of precision medicine initiatives, a rising number of regulatory approvals for rare disease treatments, the growing adoption of advanced genetic testing, and improved healthcare access for rare genetic disorders. Key trends observed in this period encompass the broader approval of gene therapies for inherited retinal diseases, an increased focus on early genetic screening and diagnosis, an expansion in clinical trials for novel retinal regeneration therapies, the rising use of assistive vision technologies, and ongoing advancements in retinal prosthesis and bionic eye solutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22033&type=smp

What Drivers Are Guiding Growth Patterns In The Leber Congenital Amaurosis Market?

The rising occurrence of inherited retinal disorders is projected to boost the expansion of the leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are defined as genetic conditions impacting the retina, which is the light-responsive tissue located at the posterior of the eye and crucial for sight. This surge in inherited retinal diseases stems from advancements in genetic testing, heightened awareness and diagnostic capabilities, and extended life spans. Improved genetic testing technologies have facilitated the diagnosis of these conditions, resulting in a greater number of identified cases. Leber congenital amaurosis contributes to a deeper understanding of inherited retinal diseases by uncovering genetic mutations and mechanisms of the disease, which in turn aids in the creation of specific therapies and interventions. For example, data from January 2025, provided by the UK Parliament’s House of Commons Library, a UK-based government body, indicated that around 25,000 individuals in the UK suffered from inherited retinal diseases in 2024, representing an annual rise of 2%. Consequently, the growing incidence of inherited retinal diseases fuels the leber congenital amaurosis market.

How Is The Leber Congenital Amaurosis Market Divided Into Segments?

The leber congenital amaurosis market covered in this report is segmented –

1) By Treatment Type: Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices, Other Treatments

2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth), Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years), Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)

3) By Distribution Channel: Direct Tender, Retail Sales

4) By End User: Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings, Other End Users

Subsegments:

1) By Gene Therapy: RPE65 Gene Replacement Therapy, CRISPR-Based Gene Editing, AAV (Adeno-Associated Virus) Vector Therapy, Emerging Experimental Gene Therapies

2) By Pharmaceutical Drugs: Retinoid-Based Therapies, Neuroprotective Agents, Anti-Inflammatory Drugs, Antioxidant Therapies

3) By Retinal Prosthesis: Implantable Retinal Chips, Artificial Retinal Stimulation Devices, Bionic Eye Technology

4) By Assistive Devices: Low Vision Aids, Screen Readers and Braille Devices, Mobility Aids for Vision Impairment

5) By Other Treatments: Stem Cell Therapy, Optogenetics-Based Treatments, Visual Rehabilitation Programs, Nutritional and Dietary Interventions

Which Competitive Trends Are Impacting The Structure Of The Leber Congenital Amaurosis Market?

Key companies active in the leber congenital amaurosis market are concentrating on developing innovative approaches, including RNA-based treatments, to improve vision restoration and disease management. RNA molecules are utilized in these treatments to address diseases by targeting genetic processes, encompassing mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For example, in January 2025, Laboratoires Théa S.A.S., a pharmaceutical firm from France, launched Sepul Bio, a dedicated unit aimed at progressing RNA therapies for inherited retinal diseases. This specifically includes sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. With the successful dosing of the initial patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is prepared to make considerable progress in tackling these rare genetic conditions.

Which Leading Companies Dominate The Leber Congenital Amaurosis Market Share?

Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., Ophthotech Corporation, Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Leber Congenital Amaurosis Market?

North America was the largest region in the leber congenital amaurosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Leber Congenital Amaurosis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22033&type=smp

Browse Through More Reports Similar to the Global Leber Congenital Amaurosis Market 2026, By The Business Research Company

Gauchers Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Congenital Heart Disease Chd Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795